May. 12 at 8:12 PM
$GUTS Summary:
* Q1 2026 net income of
$9.2 million versus
$23.7 million loss in 2025
* R&D expenses decreased to
$15.6 million from
$19.4 million year-over-year
* Adjusted EBITDA loss narrowed to
$18.0 million from
$23.0 million
* Operating expenses
$3.9 million lower year-over-year in Q1 2026
* Cash and equivalents of
$6.2 million with runway into early 2027
* REMAIN-1 Pivotal Cohort randomization completed, pivotal data expected early Q4 2026
* FDA feedback indicates Revita DMR safety profile consistent with Class II device classification (DeNovo Path to approval)
* CTA authorization in Netherlands enables first-in-human RJVA-001 study in T2D in 2026
This is excellent news for
$GUTS.
Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn.
Let's make some (more) money. Cheers!
$XBI $BSX $LLY $NVO
